Butyrylcholinesterase: impact on symptoms and progression of cognitive impairment

References

• Gauthier S, Gelinas I, Gauthier L. Functional disability in Alzheimer’s disease. Int. Psychogeriatrics9, 163–165 (1997).
   Google Scholar
• Haupt M, Kurz A, Janner M. A 2-year follow-up of behavioural and psychological symptoms in Alzheimer’s disease. Dementia Geriatric Cog. Dis.11, 147–152 (2000).
   PubMed Web of Science ®Google Scholar
• Burns A, Zaudig M. Mild cognitive impairment in older people. Lancet360, 1963–1965 (2002).
   PubMed Web of Science ®Google Scholar
• Sano M. Prevention of Alzheimer’s disease: where we stand. Curr. Neurol. Neurosci. Reports2, 392–399 (2002).
   Google Scholar
• Davies P, Maloney AJ. Selective loss of central cholinergic neurons in Alzheimer’s disease. Lancet2, 1403 (1976).
   PubMed Web of Science ®Google Scholar
• Bartus RT, Dean RL, Beer B, Lippa AS. The cholinergic hypothesis of geriatric memory dysfunction. Science217, 408–414 (1982).
   PubMed Web of Science ®Google Scholar
• Gallagher M, Colombo PJ. Ageing: the cholinergic hypothesis of cognitive decline. Current Opini. Neurobiol.5, 161–168 (1995).
   PubMed Web of Science ®Google Scholar
• Kasa P, Rakonczay Z, Gulya K. The cholinergic system in Alzheimer’s disease. Progress Neurobiol.52, 511–535 (1997).
   PubMed Web of Science ®Google Scholar
• Whitehouse PJ, Price DL, Struble RG, Clark AW, Coyle JT, Delon MR. Alzheimer’s disease and senile dementia: loss of neurons in the basal forebrain. Science215, 1237–1239 (1982).
   PubMed Web of Science ®Google Scholar
• Mesulam MM. The systems-level organisation of cholinergic innervation in the cerebral cortex and its alterations in Alzheimer’s disease. Progress Brain Res.109, 285–298 (1996).
   Google Scholar
• Katzman R. Alzheimer’s disease. N. Engl. J. Med.314, 964–973 (1986).
   PubMed Web of Science ®Google Scholar
• Blusztjan JK, Wurtman RJ. Choline and cholinergic neurons. Science221, 614–621 (1983).
   Google Scholar
• Newhouse PA, Sunderland T, Tariot PN, Blumhardt MA, Weingartner H, Mellow A. Intravenous nicotine in Alzheimer’s disease: a pilot study. Psychopharmacology95, 171–175 (1988).
   PubMed Web of Science ®Google Scholar
• O’Brien KK, Saxby BK, Ballard CG et al. Regulation of attention and response to therapy in dementia by butyrylcholinesterase. Pharmacogenetics13, 231–239 (2003).
   PubMedGoogle Scholar
• Lanctot KL, Herrmann N, Tyau KK et al. Efficacy and safety of cholinesterase inhibitors in Alzheimer’s disease: a meta-analysis. Can. Med. Assoc. J.169, 557–564 (2003).
   PubMed Web of Science ®Google Scholar
• Mintzer JE, Kershaw P. The efficacy of galantamine in the treatment of Alzheimer’s disease: comparison of patients previously treated with acetylcholinesterase inhibitors to patients with no prior exposure. Int. J. Geriatric Psych.18, 292–297 (2003).
   PubMed Web of Science ®Google Scholar
• Joffres C, Bucks RS, Haworth J, Wilcock GK, Rockwood K. Patterns of clinically detectable treatment effects with galantamine: a qualitative analysis. Dementia Geriatric Cog. Dis.15, 26–33 (2003).
   Google Scholar
• Erkinjuntti T, Skoog I, Lane R, Andrews C. Rivastigmine in patients with Alzheimer’s disease and concurrent hypertension. Int. J. Clin. Prac.56, 791–796 (2002).
   PubMed Web of Science ®Google Scholar
• Rosler M. The efficacy of cholinesterase inhibitors in treating the behavioural symptoms of dementia. Int. J. Clin. Prac.127, 20–36 (2002).
   Google Scholar
• Birks JS, Harvey R. Donepezil for dementia due to Alzheimer’s disease. Cochrane Dementia and Cognitive Improvement Group. Cochrane Database Syst. Rev.2 (2004).
   Google Scholar
• Stahl SM. The new cholinesterase inhibitors for Alzheimer’s disease. Part 1: their similarities are different. J. Clin. Psychiatry61, 710–711 (2000).
   PubMed Web of Science ®Google Scholar
• Clegg A, Bryant J, Nicholson T et al.Clinical and cost effectiveness of donepezil, rivastigmine and galantamine for Alzheimer’s disease NICE report. (2001).
   Google Scholar
• Doody RS, Stevens JC, Beck C et al. Practice parameter: management of dementia (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology56, 1154–1166 (2001).
   PubMed Web of Science ®Google Scholar
• Mani RB. The evaluation of disease modifying therapies in Alzheimer’s disease: a regulatory viewpoint. Stat. Med.23, 305–314 (2004).
   PubMed Web of Science ®Google Scholar
• Mesulam MM, Guillozet A, Shaw P, Levey A, Duysen EG, Lockridge O. Acetylcholinesterase knockouts establish central cholinergic pathways and can use butyrylcholinesterase to hydrolyse acetylcholine. Neuroscience110, 627–639 (2002).
   PubMed Web of Science ®Google Scholar
• Massoulie J, Bon S. The molecular forms of cholinesterase and acetylcholinesterase in vertebrates. Ann. Rev. Neurosci.5, 57–106 (1982).
   PubMed Web of Science ®Google Scholar
• Atack JR, Perry EK, Bonham JR, Candy JM, Perry RH. Molecular forms of acetylcholinesterase and butyrylcholinesterase in the aged human central nervous system. J. Neurochem.47, 263–277 (1986).
   PubMed Web of Science ®Google Scholar
• Wright CI, Geula C, Mesulam MM. Neuroglial cholinesterases in the normal brain and in Alzheimer’s disease: relationship to plaques, tangles and patterns of selective vulnerability. Ann. Neurol.34, 373–384 (1993).
   PubMed Web of Science ®Google Scholar
• Giacobini E. Metabolic relations between glia and neurons studied in single cells. In: Morphological and Biochemical Correlates of Neural Activity. Cohen MM, Snider RS (Eds). Harper and Row, NY, USA (1964).
   Google Scholar
• Darvesh S, Grantham DL, Hopkins DA. Distribution of butyrylcholinesterase in the human amygdala and hippocampal formation. J. Comparative Neurol.393, 374–390 (1998).
   PubMed Web of Science ®Google Scholar
• Mesulam MM, Guillozet A, Shaw P, Quinn B. Widely spread butyrylcholinesterase can hydrolyse acetylcholine in the normal and Alzheimer brain. Neurobiol. Dis.9, 88–93 (2002).
   PubMed Web of Science ®Google Scholar
• Darvesh S, Hopkins DA. Differential distribution of butyrylcholinesterase and acetylcholinesterase in the human thalamus. J. Comparative Neurol.463, 25–43 (2003).
   PubMed Web of Science ®Google Scholar
• Mesulam MM, Guillozet A, Shaw P, Levey A, Duysen EG, Lockridge O. Acetylcholinesterase knockouts establish central cholinergic pathways and can use butyrylcholinesterase to hydrolyze acetylcholine. Neuroscience110, 627–639 (2000).
   Google Scholar
• Xie W, Stribley JA, Chatonnet A et al. Postnatal developmental delay and supersensitivity to organophosphate in gene-targeted mice lacking acetylcholinesterase. J. Pharmacol. Experiment. Ther.293, 896–902 (2002).
   Google Scholar
• Giacobini E. Cholinesterase inhibitors: from the calabar bean to alzheimer therapy. In: Cholinesterases and Cholinesterase Inhibitors. Giacobini E (Ed.). Martin Dunitz Ltd, London, UK, 181–226 (2000).
   Google Scholar
• Davies P. Neurotransmitter-related enzymes in senile dementia of the Alzheimer type. Brain Res.171, 319–327 (1979).
   PubMed Web of Science ®Google Scholar
• Arendt T, Bruckner MK, Lange M, Bigl V. Changes in acetylcholinesterase and butyrylcholinesterase in Alzheimer’s disease resemble embryonic development - a study of molecular forms. Neurochem. Int.21, 381–396 (1992).
   PubMed Web of Science ®Google Scholar
• Perry EK, Perry RH, Blessed G, Tomlinson BE. Changes in brain cholinesterases in senile dementia of Alzheimer type. Neuropathol. Applied Neurobiol.4, 273–277 (1978).
   PubMed Web of Science ®Google Scholar
• Zubenko GS, Moossy J, Martinez AJ, Rao GR, Kopp U, Hanin I. A brain regional analysis of morphologic and cholinergic abnormalities in Alzheimer’s disease. Arch. Neurol.46, 634–638 (1989).
   PubMedGoogle Scholar
• Reinikainen KJ, Reinikainen PJ, Paljarvi L et al. Cholinergic deficit in Alzheimer’s disease: a study based on CSF and autopsy data. Neurochem. Res.13, 135–146 (1988).
   PubMed Web of Science ®Google Scholar
• Siek GC, Katz LS, Fishman EB, Korosi TS, Marquis JK. Molecular forms of acetylcholinesterase in subcortical areas of normal and Alzheimer’s disease brain. Biol. Psychi.27, 573–580 (1990).
   PubMed Web of Science ®Google Scholar
• Enz A, Anmstutz R, Boddeke H, Gmelin G, Malamowski J. Brain selective inhibition of acetylcholinesterase: a novel approach to therapy for Alzheimer’s disease. Prog. Brain Res.98, 431–438 (1993).
   PubMed Web of Science ®Google Scholar
• Rakonczay Z. Potencies and selectivities of inhibitors of acetylcholinesterase and its molecular forms in normal and Alzheimer’s disease brain. Acta Biologica54, 183–189 (2003).
   Google Scholar
• Mesulam MM, Geula C. Butyrylcholinesterase reactivity differentiates the amyloid plaques of aging from those of dementia. Ann. Neurol.36, 722–727 (1994).
   PubMed Web of Science ®Google Scholar
• Mesulam MM, Moran MA. Cholinesterases within neurofibrillary tangles related to age and Alzheimer’s disease. Ann. Neurol.22, 223–228 (1987).
   PubMed Web of Science ®Google Scholar
• Geula C, Mesulam MM. Cholinesterases and the pathology of Alzheimer’s disease. Alzheimer’s Dis. Ass. Dis.9, 23–28 (1995).
   Google Scholar
• Guillozet AL, Smiley JF, Mash DC, Mesulam MM. Butyrylcholinesterase in the life cycle of amyloid plaques. Ann. Neurol.42, 909–918 (1997).
   PubMed Web of Science ®Google Scholar
• Barber KL, Mesulam MM, Kraft GA, Klein WL. Butyrylcholinesterase (BuChE) alters the aggregation state of A-α amyloid. Soc. Neurosci. Abstracts22, 1172 (1996).
   Google Scholar
• Hu J, Van Eldik LJ. Glial-derived proteins activate cultured astrocytes and enhance α amyloid-induced glial activation. Brain Res.842, 46–54 (1999).
   PubMed Web of Science ®Google Scholar
• Nakamura S, Takemura M, Suenaga T et al. Occurrence of acetylcholinesterase activity closely associated with amyloid α/A4 protein is not correlated with acetylcholinesterase-positive fiber dinsity in amygdala of Alzheimer’s disease. Acta Neuropathologica84, 425–432 (1992).
   Google Scholar
• Inestrosa NC, Alvarez A, Perez CA et al. Acetylcholinesterase accelerates assembly of amyloid-α-peptides into Alzheimer’s fibrils: possible role of the peripheral site of the enzyme. Neurone16, 881–891 (1996).
   PubMed Web of Science ®Google Scholar
• Rees T, Hammond PI, Soreq H, Younkin S, Brimijoin S. Acetylcholinesterase promotes α-amyloid plaques in cerebral cortex. Neurobiol. Aging24, 777–787 (2003).
   PubMed Web of Science ®Google Scholar
• Zhang X. Cholinergic activity and amyloid precursor protein processing in aging and Alzheimer’s disease. Curr. Drug Targets CNS Neurol. Dis.3, 137–152 (2004).
   PubMedGoogle Scholar
• Piazzi L, Rampa A, Bisi A et al. 3-(4-{[Benzyl(methyl)amino]methyl}-phenyl)-6,7-dimethoxy-2H-2-chromenone(AP2238) inhibits both acetylcholinesterase and acetylcholinesterase-induced α-amyloid aggregation: a dual function lead for Alzheimer’s disease therapy. J. Med. Chem.46, 2279–2282 (2003).
   PubMed Web of Science ®Google Scholar
• Lahiri DK, Bailey J, Alley G, Chen D, Farlow M, Greig NH. Recent advanves on cholinesterase inhibitors and amyloid-α protein: implications in Alzheimer’s disease. Neurobiol. Aging25, S1–S30 (2004).
   Google Scholar
• Giacobini E. Cholinergic function and Alzheimer’s disease. Int. J. Geriatric Psych.18, S1–S5 (2003).
   Web of Science ®Google Scholar
• La Du BN, Bartels CF, Nogueira CP et al. Phenotypic and molecular biological analysis of human butyrylcholinesterase variants. Clin. Biochem.23, 423–431 (1990).
   PubMed Web of Science ®Google Scholar
• McGuire MC, Nogueira CP, Bartels CF et al. Identification of the structural mutation responsible for the dibucaine-resistant (atypical) variant form of human serum cholinesterase. Proc. Nat. Acad. Sci. USA86, 953–957 (1989).
   PubMed Web of Science ®Google Scholar
• Perry EK, McKeith IG, Ballard CG. Butyrylcholinesterase and progression of cognitive deficits in dementia with Lewy bodies. Neurology60, 1852–1853 (2003).
   PubMed Web of Science ®Google Scholar
• Wiebusch H, Poirier J, Sevigny P, Schappert K. Further evidence for a synergystic association between APOE epsilon 4 and BCHE-K in confirmed Alzheimer’s disease. Human Genetics104, 158–163 (1999).
   PubMed Web of Science ®Google Scholar
• Lehmann DJ, Johnston C, Smith AD. Synergy between the genes for butyrylcholinesterase K variant and apolipoprotein E4 in late-onset confirmed Alzheimer’s disease. Human Mol. Gen.6, 1933–1936 (1997).
   PubMed Web of Science ®Google Scholar
• Ghebremedhin E, Dietmar RT, Schultz C, Braak H. Age-dependent association between butyrylcholinesterase K-variant and Alzheimer’s disease-related neuropathology in human brains. Neurosci. Letters320, 25–28 (2002).
   Google Scholar
• Singleton AB, Smith G, Gibson AM et al. No association between the K variant of the butyrylcholinesterase gene and pathologically confirmed Alzheimer’s disease. Human Mole. Gen.7, 937–939 (1998).
   Google Scholar
• Grubber JM, Saunders AM, Crane-Gatherum AR et al. Analysis of association between Alzheimer’s disease and the K variant of butyrylcholinesterase (BCHE-K). Neurosci. Letters269, 115–119 (1999).
   Google Scholar
• Crawford F, Fallin D, Suo Z et al. The butyrylcholinesterase gene is neither independently nor synergistically associated with late-onset AD in clinic- and community-based populations. Neurosci. Letters249, 115–118 (1998).
   Google Scholar
• Corder EH, Saunders AM, Strittmatter WJ et al. Gene dose of apolipoprotein E type e4 allele and the risk of Alzheimer’s disease in late onset families. Science261, 921–923 (1993).
   PubMed Web of Science ®Google Scholar
• Navarro A, Del Valle E, Astudillo A, Gonzalez del Rey C, Tolivia J. Immunohistochemical study of distribution of apoliproproteins e and D in human cerebral α-amyloid deposits. Exp. Neurol.184, 697–704 (2003).
   PubMedGoogle Scholar
• Yu QS, Holloway HW, Flippen-Anderson JL, Hoffman B, Brossi A, Greig NH. Methyl analogues of the experimental Alzheimer drug phenserine: synthesis and structure/activity relationships for acetyl- and butyrylcholinesterase inhibitory action. J. Med. Chem.44, 4062–4071 (2001).
   PubMed Web of Science ®Google Scholar
• Yu QS, Holloway HW, Utsuki T, Brossi A, Greig NH. Synthesis of npvel phenserine-based-selective inhibitors of butyrylcholinesterase for Alzheimer’s disease. J. Med. Chem.42, 1855–1861 (1999).
   PubMed Web of Science ®Google Scholar
• Greig NH, Utsuki T, Mamczar J et al. Butyrylcholinesterase (BChE) inhibitors for the treatment of Alzheimer’s disease Society for Neuroscience Annual Meeting, CA, USA (2001).
   Google Scholar
• Greig NH, De Micheli E, Holloway HW et al. The experimental Alzheimer drug phenserine: preclinical pharmacokinetics and pharmacodynamics. Acta Neurologica Scandinavica Suppl.176, 74–84 (2000).
   PubMedGoogle Scholar
• Ikari H, Spangler EL, Greig NH et al. Maze learning in aged rats is enhanced by phenserine, a novel anticholinesterase. Neuroreport6, 481–484 (1995).
   PubMed Web of Science ®Google Scholar
• Greig NH, Ingram DK, Wang Y et al. Butyrylcholinesterase: role in memory and disease progression. Neurobiol. AgingS1–S30 (2004).
   Google Scholar
• Grieg NH, Lahiri DK, Sambamurti K. Butyrylcholinesterase: an important new target in Alzheimer’s disease therapy. Int. Psychogeriatrics14(Suppl. 1), 77–91 (2002).
   Google Scholar
• Corey-Bloom JR, Anand JV, Veach J. ENA 713 B352 Study group. A randomised control trial evaluating the efficacy and sefety of ENA 713 (rivastigmine tartrate), a new acetylcholinesterase inhibitor, in patients with mild to moderately severe Alzheimer’s disease.Int. J. Geriatric Psychopharmacol.1, 55–65 (1998).
   Google Scholar
• Farlow M, Anand R, Messina J Jr, Hartman R, Veach J. A 52-week study of the efficacy of rivastigmine in patients with mild to moderately severe Alzheimer’s disease. Eur. Neurol.44, 234–241 (2000).
   Google Scholar
• Rosler M, Anand R, Cicin-Sain A et al. Efficacy and safety of rivastigmine in patients with Alzheimer’s disease: international randomised control trial. Br. Med. J.318, 633–638 (1999).
   PubMed Web of Science ®Google Scholar
• Schneider LS, Anand R, Farlow MR. Systematic review of the efficacy of rivastigmine for patients with Alszheimer’s disease. Int. J. Geriatric Psychopharmacol.1, S2–S6 (1998).
   Google Scholar
• Burns A, Spiegel R, Quarg P. Efficacy of rivastigmine in subjects wityh moderately severe Alzheimer’s disease. Int. J. Geriatric Psych.19, 243–249 (2004).
   PubMed Web of Science ®Google Scholar